ACTRONIKA
15.12.2021 14:28:05 CET | Business Wire | Press release
The world's largest trade show dedicated to innovation is back! The 2022 edition of the Consumer Electronics Show (CES) will take place from January 5 to 8 in Las Vegas. Among the innovations presented, Actronika’s haptic vest Skinetic promises to be a sensation. Skinetic allows users to experience a new generation of immersive VR by allowing them to feel life-like sensations of every interaction within the virtual world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005507/en/
Virtual reality has evolved a lot in recent years thanks to the improvement of VR headsets. But the experience can’t be truly immersive because although they allow us to see and hear, headsets don’t let us touch. It is therefore necessary to develop haptic technologies to integrate touch into virtual experiences.
“A few players are beginning to add the sense of touch into VR. However, the tactile illusions are still very flat. We decided to take this technology from black and white to full color!” explains Gilles Meyer - CEO of Actronika
Armed with more than 30 years of expertise in haptics (science of touch), Actronika created a device to feel real-life sensations for unique virtual experiences: the Skinetic vest. From gaming to training, it enables a totally immersive experience - the user can feel every raindrop in a storm, wind when standing near a cliff edge, or even the impact of bullets during a war game.
An innovative haptic technology for maximum immersion
Skinetic stands out from the competition because of the realism and the diversity of the sensations that it provides. The vest integrates 20 patented vibrotactile voice-coil motors, capable of generating a wide range of vibrations that covers 100% of human vibrotactile perception.
To map the tactile feedback points in the vest, Actronika studied the variations in sensitivity of the human body in order to optimize the users’ perception and appreciation of the sensations.
Skinetic will be available for pre-order starting on March 22, 2022 during a one-month Kickstarter campaign.
Test the Skinetic vest during the CES at booth 60407 (Eureka Park)!
About Actronika:
Actronika is a startup specialized in haptics, reproducing the sense of touch in its customers' products. Its work is based on over 30 years of research by its cofounder Vincent Hayward, member of the French Academy of Sciences for his pioneering work in haptics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005507/en/
Link:
Social Media:
https://www.facebook.com/Skinetic.Actronika
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Investment Is Surging, but Businesses Are Struggling to Prove the Value, HTEC Global Study Finds15.10.2026 10:42:00 CEST | Press release
Research among 1,500 C-suite executives finds 77% believe people and processes now constrain AI value more than technology HTEC, a global product engineering and AI transformation company, today launches The HTEC AI Value Realization Report 2026, revealing a new challenge emerging as organizations move beyond AI experimentation: investment is accelerating faster than many companies’ ability to measure, govern and consistently realize its value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015407055/en/ HTEC, a global product engineering and AI transformation company, today launches The HTEC AI Value Realization Report 2026, revealing a new challenge emerging as organizations move beyond AI experimentation: investment is accelerating faster than many companies’ ability to measure, govern and consistently realize its value. The independent study finds that 79% of organizations have increased AI investment over the past ye
Too Good To Go Expands Its Marketplace Beyond Food15.10.2026 09:30:00 CEST | Press release
Too Good To Go, the world's largest marketplace for surplus food, today announced that it is expanding its Marketplace beyond food, enabling retailers to redistribute surplus across personal care — including skincare, haircare, oral care and beauty products — pet care, flowers and plants, nutrition and supplements, and home, initially spanning cleaning and laundry products and décor. More than 8,500 stores already supply products across these areas, around one third of which were already working with Too Good To Go to redistribute surplus food. “In today’s society, we have built incredibly efficient processes for producing and selling things at scale, creating abundance, but we have not built the same efficiency into making sure what is left over gets used. As our lives have become more convenient, we have become less conscious of what those things are worth. We used to finish what was on the plate, find a use for what we had and instinctively pause before throwing something away. Too
Flowdesk Europe Receives Payment Institution Authorization from the ACPR Under PSD215.10.2026 09:30:00 CEST | Press release
The authorization allows Flowdesk Europe to provide custody and transfer services for fiat-denominated stablecoins, complementing its MiCA CASP authorization and regulated offering for European clients. Flowdesk, a global liquidity provider and digital asset trading and infrastructure provider, today announced that its European entity, Flowdesk Europe, has been authorized as a Payment Institution by the French Prudential Supervision and Resolution Authority, l'Autorité de contrôle prudentiel et de résolution (ACPR), under the second Payment Services Directive (PSD2). The authorization allows Flowdesk Europe to provide custody and transfer services for e-money tokens (EMTs), the fiat-referenced stablecoins regulated under the Markets in Crypto-Assets (MiCA) regulation, to its clients across the European Union. The authorization follows the entity’s Crypto-Asset Service Provider (CASP) authorization received from the Autorité des Marchés Financiers (AMF) under MiCA at the end of June thi
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom